Serina Therapeutics, Inc. (SER)
| Market Cap | 29.50M -48.5% |
| Revenue (ttm) | 130,000 +154.9% |
| Net Income | -21.52M |
| EPS | -2.01 |
| Shares Out | 14.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 199,353 |
| Open | 1.880 |
| Previous Close | 1.887 |
| Day's Range | 1.830 - 2.030 |
| 52-Week Range | 1.220 - 7.920 |
| Beta | 0.04 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+455.56%) |
| Earnings Date | May 14, 2026 |
About SER
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it ... [Read more]
Financial Performance
In 2025, Serina Therapeutics's revenue was $130,000, an increase of 132.14% compared to the previous year's $56,000. Losses were -$19.44 million, 74.5% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for SER stock is "Strong Buy" and the 12-month stock price target is $11.0.
News
Serina Therapeutics files to sell 16.45M shares of common stock for holders
16:01 EDT Serina Therapeutics (SER) files to sell 16.45M shares of common stock for holders
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 -
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for t...
Serina Therapeutics announces NYSE acceptance of plan to regain compliance
Serina Therapeutics (SER) reported that the NYSE has accepted the company’s business plan to regain compliance with the continued listing standards set forth in Section 1003 of the NYSE American…
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platfor...
Serina Therapeutics to Present at the 38th Annual Roth Conference
HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optim...
Serina Therapeutics names Greg Bailey co-chairman
Serina Therapeutics (SER) announced Greg Bailey, a current board director, will assume the role of co-chairman of the board of directors. Greg Bailey will serve as co-chairman of the board…
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded ...
Serina Therapeutics doses first patient in SER-252 trial
Serina Therapeutics (SER) announced that it has dosed the first patient in its Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease.
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 –
Serina Therapeutics says first patient enrolled in Phase 1b trial of SER-252
Serina Therapeutics (SER) announced that the first patient has been enrolled in the company’s Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson’s disease. The Phase ...
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
- First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1 - Company remains on track for...
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event
“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" Featuring Serina Therapeutics' CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact dr...
Serina Therapeutics files to sell 7.72M shares of common stock for holders
17:20 EST Serina Therapeutics (SER) files to sell 7.72M shares of common stock for holders
This Is Why Serina Therapeutics Stock (SER) Rocketed Today
Serina Therapeutics stock was on the rise after the company received good news from the FDA.
Serina Therapeutics announces FDA clearance of SER-252 new drug application
Serina Therapeutics (SER) announced that the FDA has cleared its investigational new drug application for SER-252, an investigational therapy for advanced Parkinson’s disease. The IND clearance allows...
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease
- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program -
Serina Therapeutics receives NYSE deficiency notice on equity standards
Serina Therapeutics (SER) received a deficiency notice from the NYSE American stating the company falls below continued listing criteria due to insufficient shareholders’ equity and recent losses. The...
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity
HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New ...
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry
HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New ...
Serina Therapeutics submits complete response to FDA clinical hold letter
Serina Therapeutics (SER) has submitted a complete response to the FDA’s clinical hold letter for SER-252, the company’s lead program for advanced Parkinson’s disease. The FDA had placed the company’s...
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
– Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FD...
Serina Therapeutics reports Q3 EPS (45c) vs. 13c last year
Cash and cash equivalents totaled $8.6M as of September 30, 2025.
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New ...
Serina Therapeutics says FDA places clinical hold on IND for SER-252
Serina Therapeutics (SER) announced that the U.S. FDA has placed a clinical hold on the company’s Investigational New Drug application for SER-252, Serina’s lead development program for advanced Parki...